Which markers are included in the Uro-2 panel?

• A. p53 - cells with p53 mutation - nuclear; CK20 - Carcinoma in-situ cells (CIS) - cytoplasmic
• B. p53 - nuclear; CK7 - cytoplasmic
• C. CK20 - CIS; p16 - cytoplasmic
• D. CK20 - CIS; Ki-67 - nuclear

Answer: (A)

The Uro-2 panel is designed to detect two features that help identify urothelial carcinoma with CIS: p53 status and CK20 expression patterns. p53 staining is interpreted by its location in the nucleus, where abnormal tumors often show strong nuclear accumulation due to mutation. CK20 in CIS shows a distinct cytoplasmic staining pattern that spans the full thickness of the urothelium, reflecting diffuse CIS involvement.

Thus, the best choice pairing p53 with nuclear staining and CK20 with cytoplasmic staining in CIS fits what the Uro-2 panel is meant to reveal. The other options mix markers or localization patterns that aren’t characteristic of this panel or CIS assessment (for example, markers not typically included in Uro-2 or incorrect staining locales).